Background: Locus heterogeneity, wherein a disease can be caused in different individuals by different genes and/or environmental factors, is a ubiquitous feature of complex traits. A Bayesian approach has been proposed to account for variable rates of heterogeneity across families in a parametric linkage analysis setup [Biswas and Lin: J Am Stat Assoc 2006;101:1341–1351]. As with any parametric approach, its application requires specification of the disease model, which limits its practical utility. Methods: We address this limitation by proposing a Bayesian model averaging (BMA) approach. We consider a finite number of disease models and treat the model as an unknown parameter. In practice, we use simple single-locus disease models as various categories for model. Results: Our simulations as well as analysis of Genetic Analysis Workshop 13 simulated data show that BMA retains at least 80% of the power that is obtained by analyzing under the true disease model. The coverage probability of interval for disease gene is maintained around the nominal level. Finally, we apply BMA to a Late-Onset Alzheimer’s Disease dataset and find evidence for linkage on chromosomes 19, 9, and 21. Conclusion: We conclude that the BMA approach utilizing simple single-locus models for averaging is effective for mapping heterogeneous traits.

Keywords:
Linkage analysis, Locus heterogeneity, Markov chain Monte Carlo, Reversible jump, Alzheimer’s disease
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.